We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Watson Settles Lidoderm Patent Case, Wins Exclusivity After Approval
Watson Settles Lidoderm Patent Case, Wins Exclusivity After Approval
June 5, 2012
Watson Pharmaceuticals could launch its generic version of Endo Pharmaceuticals’ pain patch Lidoderm (lidocaine 5%) on Sept. 15, 2003, if the drugmaker gains FDA approval.